The Ubiquitin-Specific Protease 17-like (USP17L) family encompasses a group of deubiquitinating enzymes that play a crucial role in cellular regulation by mediating the removal of ubiquitin tags from specific substrate proteins. This deubiquitination process is fundamental to a variety of cellular functions, including cell cycle progression, signal transduction, and stress response mechanisms. By cleaving ubiquitin from substrates, USP17L enzymes facilitate the recycling of ubiquitin, prevent unwarranted proteasomal degradation of proteins, and modulate the functional state of these proteins. The activity of USP17L is therefore integral to the maintenance of protein homeostasis, influencing both the stability and activity of key regulatory proteins within various signaling pathways. This positions USP17L at the nexus of critical cellular processes, underscoring its importance in cellular dynamics and homeostasis.
Activation of USP17L enzymes is tightly regulated and can be mediated through several mechanisms, ensuring that deubiquitination occurs in a controlled manner. One primary mechanism involves post-translational modifications (PTMs) of the USP17L enzyme itself, such as phosphorylation, which can enhance its enzymatic activity or alter its specificity for substrates. Additionally, the interaction of USP17L with specific regulatory proteins can modulate its activity; such interactions may serve to recruit USP17L to particular cellular compartments or to specific substrate proteins, thereby facilitating targeted deubiquitination. Furthermore, changes in cellular conditions, such as stress signals or DNA damage, can trigger the upregulation of USP17L expression, enhancing its activity in response to cellular needs. This multilayered regulation of USP17L activity highlights the complex interplay between deubiquitinating enzymes and cellular signaling pathways, reflecting the sophisticated mechanisms cells employ to maintain equilibrium and respond to environmental cues. Through these mechanisms, the activation of USP17L contributes to the orchestration of cellular processes, ensuring the appropriate regulation of protein function and stability in response to the dynamic intracellular environment.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin raises intracellular cAMP levels, which can activate PKA. PKA phosphorylation can increase USP17L activity by facilitating its access to substrates involved in deubiquitination processes. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG inhibits several protein kinases, potentially reducing competitive inhibition on substrates of USP17L, thereby enhancing USP17L deubiquitination activity. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, which may enhance USP17L activity by modulating calcium-dependent signaling pathways involved in protein deubiquitination. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases 1 and 2A; inhibition of these phosphatases can increase phosphorylation levels of proteins, which may indirectly enhance the substrate availability for USP17L. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that can modulate AKT signaling. Reduced AKT activity might decrease phosphorylation-dependent ubiquitination, indirectly increasing the substrate pool for USP17L. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
S1P engages with G-protein-coupled receptors to activate downstream signaling that can include deubiquitination processes, potentially enhancing USP17L activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin disrupts ER calcium storage, leading to increased cytosolic calcium concentration, which could promote USP17L activity by influencing calcium-sensitive deubiquitinating enzymes. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates PKC which may have downstream effects on deubiquitination processes, indirectly enhancing USP17L function. | ||||||
Sodium Orthovanadate | 13721-39-6 | sc-3540 sc-3540B sc-3540A | 5 g 10 g 50 g | $45.00 $56.00 $183.00 | 142 | |
Sodium orthovanadate is a general inhibitor of tyrosine phosphatases, which could lead to increased tyrosine phosphorylation, potentially affecting protein interactions and stability, indirectly enhancing USP17L activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. Inhibition of p38 MAPK can alter signaling cascades and stress responses, potentially increasing the activity of USP17L by modulating its substrate interactions. | ||||||